Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee

Digestive and Liver Disease

Volumn 42, Issue 4, 2010, Pages 272-282

  Loria, P ^a   Adinolfi, L E ^b   Bellentani, S ^c   Bugianesi, E ^d   Grieco, A ^e   Fargion, S ^f   Gasbarrini, A ^e   Loguercio, C ^g   Lonardo, A ^a   Marchesini, G ^h   Marra, F ⁱ   Persico, M ^b   Prati, D ^j,k   Baroni, G Svegliati ^l  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Ospedale di Carpi   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Centro Interuniversitario per Ricerche su Alimenti Nutrizione e Apparato Digerente   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j Dipartimento di Medicina Trasfusionale   (Italy)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^l UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

more..

Author keywords

Diagnosis and management; Fibrosis; Metabolic syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMIODARONE; ANTIVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; COCAINE; DIDANOSINE; ESTROGEN DERIVATIVE; FIALURIDINE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIVER ENZYME; LOSARTAN; METFORMIN; METHOTREXATE; OMEGA 3 FATTY ACID; PEGINTERFERON; PERHEXILINE MALEATE; RIBAVIRIN; SIBUTRAMINE; TAMOXIFEN; TETRACYCLINE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; BARIATRIC SURGERY; BEHAVIOR THERAPY; BIOCHEMISTRY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; HEPATITIS C; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; ITALY; LABORATORY TEST; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPIDOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MEDICAL EXPERT; MENTAL DISEASE; METABOLIC SYNDROME X; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SYMPTOM; VASCULAR DISEASE;

FATTY LIVER; HUMANS; ITALY; SOCIETIES, MEDICAL;

EID: 77649340353     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.01.021     Document Type: Article

References (158)

1. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 2 Suppl. 1 (2006) S99-S112
2. Lazo M., and Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 28 (2008) 339-350
3. Baumeister S.E., Völzke H., Marschall P., et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 134 (2008) 85-94
4. Adams L.A., Lymp J.F., St. Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
5. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1702-1704
6. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37 (2003) 1202-1219 Review. Erratum in: Hepatology 2003; 38: 536
7. Farrell G.C., Chitturi S., Lau G.K., et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 22 (2007) 775-777
8. Zeng M.D., Fan J.G., Lu L.G., et al. Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis (2008)
9. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
10. Jou J., Choi S.S., and Diehl A.M. Mechanisms of disease progression in non-alcoholic fatty liver disease. Semin Liver Dis 28 (2008) 370-379
11. Musso G., Gambino R., and Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48 (2009) 1-26
12. Tiniakos D.G., Vos M.B., and Brunt E.M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 5 (2010) 145-171
13. Centre for EBM (CEBM) of Oxford and CEVEAS - Piano nazionale linee guida http://www.pnlg.it/.
14. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25 (2007) 883-889
15. Loria P., Lonardo A., Bellentani S., et al. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis 17 (2007) 684-698
16. Lonardo A., Carani C., Carulli N., et al. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 44 (2006) 1196-1207
17. Harmon R.C., and Caldwell S.H. Propensity for non-alcoholic fatty liver disease: more evidence for ethnic susceptibility. Liver Int 29 (2009) 4-5
18. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
19. Yu A.S., and Keeffe E.B. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence?. Am J Gastroenterol 98 (2003) 955-956
20. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 (2005) 44-52
21. Mofrad P., Contos M.J., Haque M., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37 (2003) 1286-1292
22. Fracanzani A.L., Valenti L., Bugianesi E., et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48 (2008) 792-798
23. Bedogni G., Miglioli L., Masutti F., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 46 (2007) 1387-1391
24. Hamaguchi M., Kojima T., Takeda N., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
25. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004) 750-755
26. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
27. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol November (2008)
28. Gastaldelli A., Kozakova M., Højlund K., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49 (2009) 1537-1544
29. Dunn W., Xu R., Wingard D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103 (2008) 2263-2271
30. Friis-Liby I., Aldenborg F., Jerlstad P., et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 39 (2004) 864-869
31. Adams L.A., Waters O.R., Knuiman M.W., et al. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104 (2009) 861-867
32. de Alwis N.M., and Day C.P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48 Suppl. 1 (2008) S104-S112
33. Powell E.E., Cooksley W.G., Hanson R., et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11 (1990) 74-80
34. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 22 (1995) 1714-1719
35. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
36. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
37. Ratziu V., Bonyhay L., Di Martino V., et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 35 (2002) 1485-1493
38. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003) 2042-2047
39. Hui J.M., Kench J.G., Chitturi S., et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003) 420-427
40. Fassio E., Alvarez E., Domínguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
41. Day C.P. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 129 (2005) 375-378
42. Lonardo A., Loria P., Adinolfi L.E., et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 13 (2006) 73-80
43. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
44. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33 (2000) 106-115
45. Poynard T., Ratziu V., McHutchison J., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
46. Conjeevaram H.S., Kleiner D.E., Everhart J.E., et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45 (2007) 80-87
47. Adinolfi L.E., Ingrosso D., Cesaro G., et al. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 41 (2005) 995-1003
48. Zampino R., Ingrosso D., Durante-Mangoni E., et al. Microsomal triglyceride transfer protein (MTP)-493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat 15 (2008) 740-746
49. Svegliati-Baroni G., Bugianesi E., Bouserhal T., et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 56 (2007) 1296-1301
50. Targher G., Bertolini L., Padovani R., et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46 (2007) 1126-1132
51. Tsochatzis E., Patheodoridis G.V., Manesis E.K., et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 27 (2008) 80-89
52. Lonardo A., Ballestri S., Adinolfi L.E., et al. Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. Can J Gastroenterol 23 (2009) 273-278
53. Fartoux L., Poujol-Robert A., Guéchot J., et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54 (2005) 1003-1008
54. Leandro G., Mangia A., Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130 (2006) 1636-1642
55. Westin J., Nordlinder H., Lagging M., et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37 (2002) 837-842
56. Castéra L., Hézode C., Roudot-Thoraval F., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003) 288-292
57. Cross T.J., Quaglia A., Hughes S., et al. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat 16 (2009) 492-499
58. Ohata K., Hamasaki K., Toriyama K., et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97 (2003) 3036-3043
59. Pekow J.R., Bhan A.K., Zheng H., et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109 (2007) 2490-2496
60. Takuma Y., Nouso K., Makino Y., et al. Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. Liver Int 27 (2007) 620-626
61. Tanaka A., Uegaki S., Kurihara H., et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 13 (2007) 5180-5187
62. Harrison S.A., Brunt E.M., Qazi R.A., et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3 (2005) 604-609
63. Mangia A., Minerva N., Bacca D., et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 49 (2009) 358-363
64. Bressler B.L., Guindi M., Tomlinson G., et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003) 639-644
65. Romero-Gómez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
66. D'Souza R., Sabin C.A., and Foster G.R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100 (2005) 1509-1515
67. Adinolfi L.E., Durante-Mangoni E., Zampino R., et al. Review article: hepatitis C virus-associated steatosis-pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 22 Suppl. 2 (2005) 52-55
68. Loguercio C., De Simone T., D'Auria M.V., et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 36 (2004) 398-405
69. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
70. Zeuzem S., Alberti A., Rosenberg W., et al. Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. Aliment Pharmacol Ther 24 (2006) 1133-1149
71. Loria P., Lonardo A., and Carulli N. Should nonalcoholic fatty liver disease be renamed?. Dig Dis 23 (2005) 72-82
72. Setji T.L., Holland N.D., Sanders L.L., et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 1741-1747
73. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 355 (2000) 2181-2182
74. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
75. Pinzani M., Vizzutti F., Arena U., et al. Technology Insight: non-invasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 95-106
76. Charlton M., Angulo P., Chalasani N., et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 47 (2008) 484-492
77. Loria P., Carulli L., Bertolotti M., et al. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 6 (2009) 236-247
78. Wilfred de Alwis N.M., and Day C.P. Genes and nonalcoholic fatty liver disease. Curr Diab Rep 8 (2008) 156-163
79. Kotronen A., Peltonen M., Hakkarainen A., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137 (2009) 865-872
80. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
81. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 118 (2000) 1117-1123
82. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001 Jul) 91-100
83. Angulo P., Hui J.M., Marchesini G., Bugianesi E., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007) 846-854
84. Harrison S.A., Oliver D., Arnold H.L., et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (2008) 1441-1447
85. Campos G.M., Bambha K., Vittinghoff E., et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47 (2008) 1916-1923
86. Guha I.N., Parkes J., Roderick P., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47 (2008) 455-460
87. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
88. Mathiesen U.L., Franzén L.E., Aselius H., et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 34 (2002) 516-522
89. Strauss S., Gavish E., Gottlieb P., et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 189 (2007) W320-W323
90. Roldan-Valadez E., Favila R., Martínez-López M., et al. Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 7 (2008) 212-220
91. Palmentieri B., de Sio I., La Mura V., et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 38 (2006) 485-489
92. Dasarathy S., Dasarathy J., Khiyami A., et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51 (2009) 1061-1067
93. Oliva M.R., Mortele K.J., Segatto E., et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 30 (2006) 37-43
94. Mehta S.R., Thomas E.L., Bell J.D., et al. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 14 (2008) 3476-3483
95. Yoneda M., Yoneda M., Fujita K., et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 56 (2007) 1330-1331
96. Yoneda M., Yoneda M., Mawatari H., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis (2008)
97. Friedrich-Rust M., Ong M.F., Martens S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134 (2008) 960-974
98. Wong G.L., Wong V.W., Choi P.C., et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 6 (2008) 1027-1035
99. Castéra L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology November (2009)
100. Brunt E.M. Pathology of fatty liver disease. Mod Pathol 20 Suppl. 1 (2007) S40-S48
101. Campbell M.S., and Reddy K.R. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 20 (2004) 249-259
102. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 49 (2009) 1017-1044
103. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 September (1999) 2467-2474
104. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
105. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
106. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 18 (2002) 1221-1231
107. Bellentani S., Saccoccio G., Costa G., et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 41 (1997) 845-850
108. Vuppalanchi R., and Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49 (2009) 306-317
109. Suzuki A., Angulo P., St. Sauver J., et al. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 102 (2007) 1912-1919
110. Dunn W., Xu R., and Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 47 (2008) 1947-1954
111. Gunji T., Matsuhashi N., Sato H., et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am J Gastroenterol 104 (2009) 2189-2195
112. Corrao G., Zambon A., Bagnardi V., et al. Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: an explorative case-control study. Eur J Epidemiol 19 (2004) 861-869
113. Naveau S., Giraud V., Borotto E., et al. Excess weight risk factor for alcoholic liver disease. Hepatology 25 (1997) 108-111
114. Ruhl C.E., and Everhart J.E. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 3 (2005) 1260-1268
115. Niemelä O. Biomarkers in alcoholism. Clin Chim Acta 377 (2007) 39-49
116. Ferreira M.P., and Weems M.K. Alcohol consumption by aging adults in the United States: health benefits and detriments. J Am Diet Assoc 108 (2008) 1668-1676
117. Musshoff F., and Daldrup T. Determination of biological markers for alcohol abuse. J Chromatogr B: Biomed Sci Appl 713 (1998) 245-264
118. Hannuksela M.L., Liisanantti M.K., Nissinen A.E., et al. Biochemical markers of alcoholism. Clin Chem Lab Med 45 (2007) 953-961
119. Nalpas B., Hispard E., Thépot V., et al. A comparative study between carbohydrate-deficient transferrin and gamma-glutamyltransferase for the diagnosis of excessive drinking in a liver unit. J Hepatol 27 (1997) 1003-1008
120. Hock B., Schwarz M., Domke I., et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 100 (2005) 1477-1486
121. Huseby N.E., Nilssen O., and Kanitz R.D. Evaluation of two biological markers combined as a parameter of alcohol dependency. Alcohol Alcohol 32 (1997) 731-737
122. Das S.K., Dhanya L., and Vasudevan D.M. Biomarkers of alcoholism: an updated review. Scand J Clin Lab Invest 68 (2008) 81-92
123. Bellentani S., Dalle Grave R., Suppini A., et al. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 47 (2008) 746-754
124. Neuschwander-Tetri B.A. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis 13 (2009) 649-665
125. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51 (2010) 121-129
126. Musso G., Gambino R., De Michieli F., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37 (2003) 909-916
127. Lê K.A., Ith M., Kreis R., et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 89 (2009) 1760-1765
128. Abid A., Taha O., Nseir W., et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 51 (2009) 918-924
129. Stanhope K.L., Schwarz J.M., Keim N.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 119 (2009) 1322-1334
130. Ryan M.C., Abbasi F., Lamendola C., et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 30 (2007) 1075-1080
131. Gasteyger C., Larsen T.M., Vercruysse F., et al. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr 87 (2008) 1141-1147
132. Krasnoff J.B., Painter P.L., Wallace J.P., et al. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 47 (2008) 1158-1166
133. St. George A., Bauman A., Johnston A., et al. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 50 (2009) 68-76
134. Sookoian S., and Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 49 (2008) 600-607
135. Helmerhorst H.J., Wijndaele K., Brage S., et al. Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity. Diabetes 58 (2009) 1776-1779
136. Neff L.M., and Aronne L.J. Pharmacotherapy for obesity. Curr Atheroscler Rep 9 (2007) 454-462
137. Lee H.K., Choi E.B., and Pak C.S. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 9 (2009) 482-503
138. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6 (2008) 1396-1402
139. Chavez-Tapia N.C., Tellez-Avila F.I., Barrientos-Gutierrez T., et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 1 (2010) CD007340
140. Moscatiello S., Marzocchi R., Villanova N., et al. Which treatment for nonalcoholic fatty liver disease?. Mini Rev Med Chem 8 (2008) 767-775
141. Ratziu. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2009) epub October 31
142. Lutchman G., Modi A., Kleiner D.E., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46 (2007) 424-429
143. Taylor C., and Hobbs F.D. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. Br J Gen Pract 59 (2009) 520-524
144. Yokohama S., Yoneda M., Haneda M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004) 1222-1225
145. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 (2004) 770-778
146. Laurin J., Lindor K.D., Crippin J.S., et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23 (1996) 1464-1467
147. Dufour J.F., Oneta C.M., Gonvers J.J., Bihl F., Cerny A., Cereda J.M., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 4 (2006) 1537-1543
148. Valenti L., Fracanzani A.L., Dongiovanni P., et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 102 (2007) 1251-1258
149. Satapathy S.K., Sakhuja P., Malhotra V., et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 22 (2007) 634-638
150. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48 (2001) 251-259
151. Sangiovanni A., Del Ninno E., Fasani P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 (2004) 1005-1014
152. Calle E.E. Obesity and cancer. Br Med J 335 (2007) 1107-1108
153. Brun E., Nelson R.G., Bennett P.H., et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care 23 (2000) 1119-1123
154. Sørensen H.T., Mellemkjaer L., Jepsen P., et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 36 (2003) 356-359
155. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol (2007) 47
156. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48 (2008) 993-999
157. Nocito A., El-Badry A.M., and Clavien P.A. When is steatosis too much for transplantation?. J Hepatol 45 (2006) 494-499
158. Forman L.M. Metabolic syndrome in liver transplantation: the elephant in the room. Liver Transplant 14 (2008) 1245-1248